Abstract
Purpose: To investigate the bioavailability and bioequivalence of three different formulations of eslicarbazepine acetate (BIA 2-093): 50 mg/mL oral suspension (test 1), 200mg tablets (test 2) and 800mg tablets (reference).
Design, subjects and methods: Single-centre, open-label, randomised, three-way crossover study in 18 healthy subjects. The study consisted of three consecutive periods separated by a washout period of 7 days or more. Each subject received a single dose of eslicarbazepine acetate 800mg on three different occasions: 16mL of oral 50 mg/mL suspension, four 200mg tablets or one 800mg tablet.
Results: Eslicarbazepine acetate was rapidly and extensively metabolised to BIA 2-005. Maximum BIA 2-005 plasma concentrations (Cmax) and area under the plasma concentration-time curve from time 0 to infinity (AUC∞) were, respectively (arithmetic mean ± SD), 18.0 ± 4.6 μg/mL and 325.7 ± 64.9 μg · h/mL for test 1, 16.0 ± 4.0 μg/mL and 304.2 ± 66.0 μg · h/mL for test 2, and 17.0 ± 4.1 μg/mL and 301.1 ± 60.0 μg · h/mL for the reference formulation. Point estimate (PE) and 90% confidence intervals (CIs) for AUC∞ test 1/reference geometric mean ratio were 1.09 and 1.01, 1.15; for Cmax ratio, PE and 90% CI were 1.07 and 0.97, 1.15. When test 2 and the reference formulations were compared, the PE and 90% CI were 0.99 and 0.94, 1.07 for the AUC∞ ratio, and 0.94 and 0.86, 1.02 for the Cmax ratio. Bioequivalence of test versus reference formulations is thus accepted for both AUC∞ and Cmax because the 90% CIs lie within the acceptance range of 0.80–1.25.
Conclusion: The pharmacokinetic profiles of eslicarbazepine acetate oral 50 mg/mL suspension, 200mg tablet and 800mg tablet formulations were essentially similar, and the formulations can be considered bioequivalent.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00126839-200506050-00001/MediaObjects/40268_2012_6050253_Fig1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00126839-200506050-00001/MediaObjects/40268_2012_6050253_Tab1.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.2165%2F00126839-200506050-00001/MediaObjects/40268_2012_6050253_Tab2.jpg)
Similar content being viewed by others
References
Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999; 42: 2582–7
Bonifacio MJ, Sheridan RD, Parada A, et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600–8
Almeida L, Falcão A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. In press.
Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R&D 2003; 4 (5): 269–84
Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in healthy humans. J Clin Pharmacol 2004; 44: 906–18
Maia J, Vaz-da-Silva M, Almeida L, et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs RD 2005; 6 (4): 201–6
Maia J, Almeida L, Soares-da-Silva P. BIA 2-093 as add-on therapy for refractory partial epilepsy patients [abstract]. Epilepsia 2004; 45 Suppl. 3: 158
Center for Drug Evaluation and Research (CDER). Bioavailability and bioequivalence studies for orally administered products: general considerations. US Department of Health and Human Services, Food and Drug Administration, Rockville (MD): 2000 Oct
Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/1401/98, The European Agency for the Evaluation of Medicinal Products (EMEA), London: 2001 Jul
Schuirmann DJ. A comparison of two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15 (6): 657–80
Acknowledgements
This study was supported by BIAL (Portela & Ca SA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fontes-Ribeiro, C., Nunes, T., Falcão, A. et al. Eslicarbazepine Acetate (BIA 2-093). Drugs R D 6, 253–260 (2005). https://doi.org/10.2165/00126839-200506050-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200506050-00001